

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

- 1-32. (Canceled)
33. (Currently Amended) An isolated protein comprising an amino acid sequence at least 90% identical to a mature form of a polypeptide of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
34. (Previously Presented) The isolated protein of claim 33, wherein said amino acid sequence is at least 95% identical to a mature form of a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
35. (Previously Presented) A fusion protein comprising the isolated protein of Claim 33 fused to a heterologous polypeptide.
36. (Previously Presented) The isolated protein of Claim 33 comprising a homodimer.
37. (Previously Presented) The isolated protein of Claim 33 which is glycosylated.
38. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 33, wherein the patient has a wound, tissue, or bone damage.
39. (Previously Presented) The method of claim 38, wherein said patient has ischemia.
40. (Previously Presented) The method of claim 38, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
41. (Previously Presented) The method of claim 38, wherein said patient has had a myocardial infarction.

42. (Previously Presented) The method of claim 38, wherein the method stimulates angiogenesis.
43. (Previously Presented) The method of claim 38, wherein the patient is a human.
44. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 33, wherein the patient has a wound, tissue, or bone damage.
45. (Previously Presented) The method of claim 44, wherein said patient has ischemia.
46. (Previously Presented) The method of claim 44, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
47. (Previously Presented) The method of claim 44, wherein said patient has had a myocardial infarction.
48. (Previously Presented) The method of claim 44, wherein said patient is a human.
- 49-64. (Canceled)
65. (Currently Amended) An isolated protein comprising an amino acid sequence at least 90% identical to a proprotein form of a polypeptide of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
66. (Previously Presented) The isolated protein of claim 65, wherein said amino acid sequence is at least 95% identical to a proprotein form of a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
67. (Previously Presented) A fusion protein comprising the isolated protein of Claim 65 fused to a heterologous polypeptide.

68. (Previously Presented) The isolated protein of Claim 65 comprising a homodimer.
69. (Previously Presented) The isolated protein of Claim 65 which is glycosylated.
70. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 65, wherein the patient has a wound, tissue, or bone damage.
71. (Previously Presented) The method of claim 70, wherein said patient has ischemia.
72. (Previously Presented) The method of claim 70, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
73. (Previously Presented) The method of claim 70, wherein said patient has had a myocardial infarction.
74. (Previously Presented) The method of claim 70, wherein the method stimulates angiogenesis.
75. (Previously Presented) The method of claim 70, wherein the patient is a human.
76. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 65, wherein the patient has a wound, tissue, or bone damage.
77. (Previously Presented) The method of claim 76, wherein said patient has ischemia.
78. (Previously Presented) The method of claim 76, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
79. (Previously Presented) The method of claim 76, wherein said patient has had a myocardial infarction.

80. (Previously Presented) The method of claim 76, wherein said patient is a human.
81. (Currently Amended) An isolated protein comprising an amino acid sequence at least 90% identical to a proprotein form of a polypeptide of SEQ ID NO:4, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
82. (Previously Presented) The isolated protein of claim 81, wherein said amino acid sequence is at least 95% identical to a proprotein form of a polypeptide comprising the amino acid sequence of SEQ ID NO:4.
83. (Previously Presented) A fusion protein comprising the isolated protein of Claim 81 fused to a heterologous polypeptide.
84. (Previously Presented) The isolated protein of Claim 81 comprising a homodimer.
85. (Previously Presented) The isolated protein of Claim 81 which is glycosylated.
86. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 81, wherein the patient has a wound, tissue, or bone damage.
87. (Previously Presented) The method of claim 86, wherein said patient has ischemia.
88. (Previously Presented) The method of claim 86, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
89. (Previously Presented) The method of claim 86, wherein said patient has had a myocardial infarction.
90. (Previously Presented) The method of claim 86, wherein the method stimulates angiogenesis.

91. (Previously Presented) The method of claim 86, wherein the patient is a human.
92. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 81, wherein the patient has a wound, tissue, or bone damage.
93. (Previously Presented) The method of claim 92, wherein said patient has ischemia.
94. (Previously Presented) The method of claim 92, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
95. (Previously Presented) The method of claim 92, wherein said patient has had a myocardial infarction.
96. (Previously Presented) The method of claim 92, wherein said patient is a human.
- 97-112. (Canceled)
113. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a mature form of a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97149, wherein said isolated protein ~~has endothelial cell~~ proliferative activity proliferates endothelial cells.
114. (Previously Presented) The isolated protein of claim 113, wherein said amino acid sequence is at least 95% identical to a mature form of a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97149.
115. (Previously Presented) A fusion protein comprising the isolated protein of Claim 113 fused to a heterologous polypeptide.
116. (Previously Presented) The isolated protein of Claim 113 comprising a homodimer.

117. (Previously Presented) The isolated protein of Claim 113 which is glycosylated.
118. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 113, wherein the patient has a wound, tissue, or bone damage.
119. (Previously Presented) The method of claim 118, wherein said patient has ischemia.
120. (Previously Presented) The method of claim 118, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
121. (Previously Presented) The method of claim 118, wherein said patient has had a myocardial infarction.
122. (Previously Presented) The method of claim 118, wherein the method stimulates angiogenesis.
123. (Previously Presented) The method of claim 118, wherein the patient is a human.
124. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 113, wherein the patient has a wound, tissue, or bone damage.
125. (Previously Presented) The method of claim 124, wherein said patient has ischemia.
126. (Previously Presented) The method of claim 124, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
127. (Previously Presented) The method of claim 124, wherein said patient has had a myocardial infarction.

128. (Previously Presented) The method of claim 124, wherein said patient is a human.
129. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a proprotein form of a polypeptide encoded by the cDNA contained in ATCC Deposit No. 75698, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
130. (Previously Presented) The isolated protein of claim 129, wherein said amino acid sequence is at least 95% identical to a proprotein form of a polypeptide encoded by the cDNA contained in ATCC Deposit No. 75698.
131. (Previously Presented) A fusion protein comprising the isolated protein of Claim 129 fused to a heterologous polypeptide.
132. (Previously Presented) The isolated protein of Claim 129 comprising a homodimer.
133. (Previously Presented) The isolated protein of Claim 129 which is glycosylated.
134. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 129, wherein the patient has a wound, tissue, or bone damage.
135. (Previously Presented) The method of claim 134, wherein said patient has ischemia.
136. (Previously Presented) The method of claim 134, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
137. (Previously Presented) The method of claim 134, wherein said patient has had a myocardial infarction.
138. (Previously Presented) The method of claim 134, wherein the method stimulates angiogenesis.

139. (Previously Presented) The method of claim 134, wherein the patient is a human.
140. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 129, wherein the patient has a wound, tissue, or bone damage.
141. (Previously Presented) The method of claim 140, wherein said patient has ischemia.
142. (Previously Presented) The method of claim 140, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
143. (Previously Presented) The method of claim 140, wherein said patient has had a myocardial infarction.
144. (Previously Presented) The method of claim 140, wherein said patient is a human.
145. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a proprotein form of a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97149, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
146. (Previously Presented) The isolated protein of claim 145, wherein said amino acid sequence is at least 95% identical to a proprotein form of a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97149.
147. (Previously Presented) A fusion protein comprising the isolated protein of Claim 145 fused to a heterologous polypeptide.
148. (Previously Presented) The isolated protein of Claim 145 comprising a homodimer.
149. (Previously Presented) The isolated protein of Claim 145 which is glycosylated.

150. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 145, wherein the patient has a wound, tissue, or bone damage.
151. (Previously Presented) The method of claim 150, wherein said patient has ischemia.
152. (Previously Presented) The method of claim 150, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
153. (Previously Presented) The method of claim 150, wherein said patient has had a myocardial infarction.
154. (Previously Presented) The method of claim 150, wherein the method stimulates angiogenesis.
155. (Previously Presented) The method of claim 150, wherein the patient is a human.
156. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 145, wherein the patient has a wound, tissue, or bone damage.
157. (Previously Presented) The method of claim 156, wherein said patient has ischemia.
158. (Previously Presented) The method of claim 156, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
159. (Previously Presented) The method of claim 156, wherein said patient has had a myocardial infarction.
160. (Previously Presented) The method of claim 156, wherein said patient is a human.

161. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide encoded by the cDNA contained in ATCC Deposit No. 75698, wherein said isolated protein ~~comprises SEQ ID NO:8 and has endothelial cell proliferative activity~~ proliferates endothelial cells.
162. (Previously Presented) The isolated protein of claim 161, wherein said amino acid sequence is at least 95% identical to a polypeptide encoded by the cDNA contained in ATCC Deposit No. 75698.
163. (Previously Presented) A fusion protein comprising the isolated protein of Claim 161 fused to a heterologous polypeptide.
164. (Previously Presented) The isolated protein of Claim 161 comprising a homodimer.
165. (Previously Presented) The isolated protein of Claim 161 which is glycosylated.
166. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 161, wherein the patient has a wound, tissue, or bone damage.
167. (Previously Presented) The method of claim 166, wherein said patient has ischemia.
168. (Previously Presented) The method of claim 166, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
169. (Previously Presented) The method of claim 166, wherein said patient has had a myocardial infarction.
170. (Previously Presented) The method of claim 166, wherein the method stimulates angiogenesis.
171. (Previously Presented) The method of claim 166, wherein the patient is a human.

172. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 161, wherein the patient has a wound, tissue, or bone damage.
173. (Previously Presented) The method of claim 172, wherein said patient has ischemia.
174. (Previously Presented) The method of claim 172, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
175. (Previously Presented) The method of claim 172, wherein said patient has had a myocardial infarction.
176. (Previously Presented) The method of claim 172, wherein said patient is a human.
177. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97149, wherein said isolated protein ~~comprises SEQ ID NO:8 and has endothelial cell proliferative activity~~ proliferates endothelial cells.
178. (Previously Presented) The isolated protein of claim 177, wherein said amino acid sequence is at least 95% identical to a polypeptide encoded by the cDNA contained in ATCC Deposit No. 97149.
179. (Previously Presented) A fusion protein comprising the isolated protein of Claim 177 fused to a heterologous polypeptide.
180. (Previously Presented) The isolated protein of Claim 177 comprising a homodimer.
181. (Previously Presented) The isolated protein of Claim 177 which is glycosylated.

182. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 177, wherein the patient has a wound, tissue, or bone damage.
183. (Previously Presented) The method of claim 182, wherein said patient has ischemia.
184. (Previously Presented) The method of claim 182, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
185. (Previously Presented) The method of claim 182, wherein said patient has had a myocardial infarction.
186. (Previously Presented) The method of claim 182, wherein the method stimulates angiogenesis.
187. (Previously Presented) The method of claim 182, wherein the patient is a human.
188. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 177, wherein the patient has a wound, tissue, or bone damage.
189. (Previously Presented) The method of claim 188, wherein said patient has ischemia.
190. (Previously Presented) The method of claim 188, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
191. (Previously Presented) The method of claim 188, wherein said patient has had a myocardial infarction.
192. (Previously Presented) The method of claim 188, wherein said patient is a human.

193. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide comprising amino acids 71 to 396 of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
194. (Previously Presented) The isolated protein of claim 193, wherein said amino acid sequence is at least 95% identical to a polypeptide comprising amino acids 71 to 396 of SEQ ID NO:2.
195. (Previously Presented) A fusion protein comprising the isolated protein of Claim 193 fused to a heterologous polypeptide.
196. (Previously Presented) The isolated protein of Claim 193 comprising a homodimer.
197. (Previously Presented) The isolated protein of Claim 193 which is glycosylated.
198. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 193, wherein the patient has a wound, tissue, or bone damage.
199. (Previously Presented) The method of claim 198, wherein said patient has ischemia.
200. (Previously Presented) The method of claim 198, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
201. (Previously Presented) The method of claim 198, wherein said patient has had a myocardial infarction.
202. (Previously Presented) The method of claim 198, wherein the method stimulates angiogenesis.
203. (Previously Presented) The method of claim 198, wherein the patient is a human.

204. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 193, wherein the patient has a wound, tissue, or bone damage.
205. (Previously Presented) The method of claim 204, wherein said patient has ischemia.
206. (Previously Presented) The method of claim 204, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
207. (Previously Presented) The method of claim 204, wherein said patient has had a myocardial infarction.
208. (Previously Presented) The method of claim 204, wherein said patient is a human.
209. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide comprising amino acids 47 to 396 of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
210. (Previously Presented) The isolated protein of claim 209, wherein said amino acid sequence is at least 95% identical to a polypeptide comprising amino acids 47 to 396 of SEQ ID NO:2.
211. (Previously Presented) A fusion protein comprising the isolated protein of Claim 209 fused to a heterologous polypeptide.
212. (Previously Presented) The isolated protein of Claim 209 comprising a homodimer.
213. (Previously Presented) The isolated protein of Claim 209 which is glycosylated.

214. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 209, wherein the patient has a wound, tissue, or bone damage.
215. (Previously Presented) The method of claim 214, wherein said patient has ischemia.
216. (Previously Presented) The method of claim 214, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
217. (Previously Presented) The method of claim 214, wherein said patient has had a myocardial infarction.
218. (Previously Presented) The method of claim 214, wherein the method stimulates angiogenesis.
219. (Previously Presented) The method of claim 214, wherein the patient is a human.
220. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 209, wherein the patient has a wound, tissue, or bone damage.
221. (Previously Presented) The method of claim 220, wherein said patient has ischemia.
222. (Previously Presented) The method of claim 220, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
223. (Previously Presented) The method of claim 220, wherein said patient has had a myocardial infarction.
224. (Previously Presented) The method of claim 220, wherein said patient is a human.

225. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide comprising amino acids 24 to 396 of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
226. (Previously Presented) The isolated protein of claim 225, wherein said amino acid sequence is at least 95% identical to a polypeptide comprising amino acids 24 to 396 of SEQ ID NO:2.
227. (Previously Presented) A fusion protein comprising the isolated protein of Claim 225 fused to a heterologous polypeptide.
228. (Previously Presented) The isolated protein of Claim 225 comprising a homodimer.
229. (Previously Presented) The isolated protein of Claim 225 which is glycosylated.
230. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 225, wherein the patient has a wound, tissue, or bone damage.
231. (Previously Presented) The method of claim 230, wherein said patient has ischemia.
232. (Previously Presented) The method of claim 230, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
233. (Previously Presented) The method of claim 230, wherein said patient has had a myocardial infarction.
234. (Previously Presented) The method of claim 230, wherein the method stimulates angiogenesis.
235. (Previously Presented) The method of claim 230, wherein the patient is a human.

236. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 225, wherein the patient has a wound, tissue, or bone damage.
237. (Previously Presented) The method of claim 236, wherein said patient has ischemia.
238. (Previously Presented) The method of claim 236, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
239. (Previously Presented) The method of claim 236, wherein said patient has had a myocardial infarction.
240. (Previously Presented) The method of claim 236, wherein said patient is a human.
241. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide comprising amino acids 1 to 396 of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
242. (Previously Presented) The isolated protein of claim 241, wherein said amino acid sequence is at least 95% identical to a polypeptide comprising amino acids 1 to 396 of SEQ ID NO:2.
243. (Previously Presented) A fusion protein comprising the isolated protein of Claim 241 fused to a heterologous polypeptide.
244. (Previously Presented) The isolated protein of Claim 241 comprising a homodimer.
245. (Previously Presented) The isolated protein of Claim 241 which is glycosylated.

246. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 241, wherein the patient has a wound, tissue, or bone damage.
247. (Previously Presented) The method of claim 246, wherein said patient has ischemia.
248. (Previously Presented) The method of claim 246, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
249. (Previously Presented) The method of claim 246, wherein said patient has had a myocardial infarction.
250. (Previously Presented) The method of claim 246, wherein the method stimulates angiogenesis.
251. (Previously Presented) The method of claim 246, wherein the patient is a human.
252. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 241, wherein the patient has a wound, tissue, or bone damage.
253. (Previously Presented) The method of claim 252 , wherein said patient has ischemia.
254. (Previously Presented) The method of claim 252 , wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
255. (Previously Presented) The method of claim 252 , wherein said patient has had a myocardial infarction.
256. (Previously Presented) The method of claim 252 , wherein said patient is a human.

257. (Currently Amended) An isolated protein comprising an amino acid sequence that is at least 90% identical to a polypeptide comprising amino acids -23 to 396 of SEQ ID NO:2, wherein said isolated protein ~~has endothelial cell proliferative activity~~ proliferates endothelial cells.
258. (Previously Presented) The isolated protein of claim 257, wherein said amino acid sequence is at least 95% identical a polypeptide comprising amino acids -23 to 396 of SEQ ID NO:2.
259. (Previously Presented) A fusion protein comprising the isolated protein of Claim 257 fused to a heterologous polypeptide.
260. (Previously Presented) The isolated protein of Claim 257 comprising a homodimer.
261. (Previously Presented) The isolated protein of Claim 257 which is glycosylated.
262. (Previously Presented) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the isolated protein of claim 257, wherein the patient has a wound, tissue, or bone damage.
263. (Previously Presented) The method of claim 262, wherein said patient has ischemia.
264. (Previously Presented) The method of claim 262, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
265. (Previously Presented) The method of claim 262, wherein said patient has had a myocardial infarction.
266. (Previously Presented) The method of claim 262, wherein the method stimulates angiogenesis.
267. (Previously Presented) The method of claim 262, wherein the patient is a human.

268. (Previously Presented) A method of stimulating angiogenesis in a patient comprising administering to the patient the isolated protein of claim 257, wherein the patient has a wound, tissue, or bone damage.
269. (Previously Presented) The method of claim 268, wherein said patient has ischemia.
270. (Previously Presented) The method of claim 268, wherein said patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.
271. (Previously Presented) The method of claim 268, wherein said patient has had a myocardial infarction.
272. (Previously Presented) The method of claim 268, wherein said patient is a human.
- 273-400. (Canceled)